The Pharmaceutical Research Center (PRC) is responsible for the safe and ethical provision of investigational/study medications to research subjects enrolled in clinical drug trials within the University of Wisconsin Hospital and Clinics (UWHC) and the University of Wisconsin Carbone Cancer Center (UWCCC). The PRC service ensures that drug research protocols proceed optimally through UWHC's established medication use system and in accordance with all federal, state, institutional and sponsor regulations governing clinical research. While the PRC program supports all UW-Madison investigators conducting clinical drug research, its relationship with UWCCC is unique in its level of commitment, the breadth and depth of services provided and its expertise in handling biohazardous and gene therapy products. The PRC provides detailed protocol review and feasibility assessment within the confines of an academic medical center. It ensures full compliance with federal, state, sponsor and institutional requirements through activities such as;establishment of drug handling/distribution/preparation/destruction procedures;creation of investigational drug monographs for health care providers;education of healthcare staff regarding protocol procedures;creation of preprinted physician orders and prescriptions;drug inventory management and accountability;drug preparation and/or oversight;quality assurance audits;and protocol amendment management. It operates satellite pharmacy locations, optimizing ability to extend clinical research into the community. The services are continually refined and expanded to meet the evolving needs of UWCCC research faculty, research infrastructure and the research subject.
The Pharmaceutical Research Center is responsible for the safe and ethical provision of study medications to research subjects enrolled in clinical drug trials within the University of Wisconsin Hospital and Clinics and the University of Wisconsin Carbone Cancer Center.
|Guerrero, Natalie; Small, Alissa L; Schwei, Rebecca J et al. (2018) Informing physician strategies to overcome language barriers in encounters with pediatric patients. Patient Educ Couns 101:653-658|
|Chapelin, Fanny; Capitini, Christian M; Ahrens, Eric T (2018) Fluorine-19 MRI for detection and quantification of immune cell therapy for cancer. J Immunother Cancer 6:105|
|Ni, Dalong; Ferreira, Carolina A; Barnhart, Todd E et al. (2018) Magnetic Targeting of Nanotheranostics Enhances Cerenkov Radiation-Induced Photodynamic Therapy. J Am Chem Soc 140:14971-14979|
|Chang, Julie E; Carmichael, Lakeesha L; Kim, KyungMann et al. (2018) VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. Clin Lymphoma Myeloma Leuk 18:e61-e67|
|Pearson, Hannah E; Iida, Mari; Orbuch, Rachel A et al. (2018) Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol. Mol Cancer Ther 17:204-214|
|Mora-Pinzon, Maria C; Trentham-Dietz, Amy; Gangnon, Ronald E et al. (2018) Urinary Magnesium and Other Elements in Relation to Mammographic Breast Density, a Measure of Breast Cancer Risk. Nutr Cancer 70:441-446|
|DuBenske, Lori L; Schrager, Sarina B; Hitchcock, Mary E et al. (2018) Key Elements of Mammography Shared Decision-Making: a Scoping Review of the Literature. J Gen Intern Med 33:1805-1814|
|Wang, Dongdong; Shi, Ruohong; Zhou, Jiajia et al. (2018) Photo-Enhanced Singlet Oxygen Generation of Prussian Blue-Based Nanocatalyst for Augmented Photodynamic Therapy. iScience 9:14-26|
|Erbe, Amy K; Wang, Wei; Carmichael, Lakeesha et al. (2018) Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clin Cancer Res 24:189-196|
|Eckers, Jaimee C; Swick, Adam D; Kimple, Randall J (2018) Identity Crisis - Rigor and Reproducibility in Human Cell Lines. Radiat Res 189:551-552|
Showing the most recent 10 out of 1528 publications